ClinicalTrials.gov
public full text
Public Domain
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML#1086817
- Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia#906153
- Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients#853185
- LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML#805504
- Master Framework For Relapse or Refractory Acute Myeloid Leukemia#908953
Record · ID 1115188
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive